<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30362387</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>11</Month>            <Day>09</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1475-6374</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>34</Volume>                    <Issue>1</Issue>                    <PubDate>                        <Year>2019</Year>                        <Month>Dec</Month>                    </PubDate>                </JournalIssue>                <Title>Journal of enzyme inhibition and medicinal chemistry</Title>                <ISOAbbreviation>J Enzyme Inhib Med Chem</ISOAbbreviation>            </Journal>            <ArticleTitle>Synthesis and cytotoxic activities of novel copper and silver complexes of 1,3-diaryltriazene-substituted sulfonamides.</ArticleTitle>            <Pagination>                <MedlinePgn>110-116</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1080/14756366.2018.1530994</ELocationID>            <Abstract>                <AbstractText>In this study, a series of 10 novel copper (II) and silver complexes of 1,3-diaryltriazene-substituted sulfonamides was synthesised. All the synthesised ligands and their metal complexes were assessed for in vitro cytotoxicity against human colorectal adenocarcinoma (DLD-1), cervix carcinoma (HeLa), breast adenocarcinoma (MDA-MB-231), colon adenocarcinoma (HT-29), endometrial adenocarcinoma (ECC-1), prostate cancer (DU-145 and PC-3), normal embryonic kidney (HEK-293), normal prostate epithelium (PNT-1A), and normal retinal pigment epithelium (ARPE-19) cells. Most of the metal complexes from the series showed to be more active against all cancerous cells than the uncomplexed 1,3-diaryltriazene-substituted sulfonamides, and lower cytotoxic effects observed on normal cells. Most of the Cu (II) and Ag (I) metal complexes from the presented series showed high cytotoxic activity against HeLa cells with IC<sub>50</sub> values ranging from 2.08 to &gt;300 µM. Specifically, compound L<sub>3</sub>-Ag showed one of the highest cytotoxicity against all cancer cell lines with IC<sub>50</sub> values between 3.30 to 16.18 µM among other tested compounds.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Canakci</LastName>                    <ForeName>Dilek</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>a Department of Chemistry , Vocational School of Technical Sciences, Adiyaman University , Adiyaman , Turkey.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Koyuncu</LastName>                    <ForeName>Ismail</ForeName>                    <Initials>I</Initials>                    <AffiliationInfo>                        <Affiliation>b Faculty of Medicine , Department of Biochemistry , Harran University , Sanliurfa , Turkey.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lolak</LastName>                    <ForeName>Nabih</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>c Faculty of Pharmacy , Department of Pharmaceutical Chemistry , Adiyaman University , Adiyaman, Turkey.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Durgun</LastName>                    <ForeName>Mustafa</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>d Faculty of Arts and Sciences , Deparment of Chemistry , Harran University , Sanliurfa , Turkey.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Akocak</LastName>                    <ForeName>Suleyman</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>c Faculty of Pharmacy , Department of Pharmaceutical Chemistry , Adiyaman University , Adiyaman, Turkey.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Supuran</LastName>                    <ForeName>Claudiu T</ForeName>                    <Initials>CT</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0003-4262-0323</Identifier>                    <AffiliationInfo>                        <Affiliation>e NEUROFARBA Department, Sezione di Scienze Farmaceutiche , Università degli Studi di Firenze , Florence , Italy.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>J Enzyme Inhib Med Chem</MedlineTA>            <NlmUniqueID>101150203</NlmUniqueID>            <ISSNLinking>1475-6366</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D013424">Sulfanilamides</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D014226">Triazenes</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>3M4G523W1G</RegistryNumber>                <NameOfSubstance UI="D012834">Silver</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>789U1901C5</RegistryNumber>                <NameOfSubstance UI="D003300">Copper</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Bioorg Chem. 2017 Feb;70:163-172</RefSource>                <PMID Version="1">28041662</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Curr Opin Chem Biol. 2008 Apr;12(2):197-206</RefSource>                <PMID Version="1">18155674</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell. 2000 Jan 7;100(1):57-70</RefSource>                <PMID Version="1">10647931</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Chem Commun (Camb). 2010 Nov 28;46(44):8371-3</RefSource>                <PMID Version="1">20922253</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Curr Pharm Des. 2010 Jun;16(16):1813-25</RefSource>                <PMID Version="1">20337575</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Med Chem. 2011 Mar 24;54(6):1896-902</RefSource>                <PMID Version="1">21361354</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Cancer. 2003 Oct;3(10):721-32</RefSource>                <PMID Version="1">13130303</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Cancer. 2002 Jan;2(1):38-47</RefSource>                <PMID Version="1">11902584</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2011 May 1;71(9):3364-76</RefSource>                <PMID Version="1">21415165</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J R Soc Interface. 2012 Mar 7;9(68):401-19</RefSource>                <PMID Version="1">22158843</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>                <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D003300" MajorTopicYN="N">Copper</DescriptorName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D004354" MajorTopicYN="N">Drug Screening Assays, Antitumor</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D012834" MajorTopicYN="N">Silver</DescriptorName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D013424" MajorTopicYN="N">Sulfanilamides</DescriptorName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D014226" MajorTopicYN="N">Triazenes</DescriptorName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Metal complexes</Keyword>            <Keyword MajorTopicYN="N">cancer cells</Keyword>            <Keyword MajorTopicYN="N">cytotoxicity</Keyword>            <Keyword MajorTopicYN="N">sulfonamides</Keyword>            <Keyword MajorTopicYN="N">triazene</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>27</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>27</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30362387</ArticleId>            <ArticleId IdType="doi">10.1080/14756366.2018.1530994</ArticleId>            <ArticleId IdType="pmc">PMC6211257</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>